Pfizer to Seek Regulatory Approval for Lyme Disease Vaccine Candidate Despite Missed Primary Endpoint in Phase 3 Trial, Citing Strong Efficacy Data.
Pfizer, a global pharmaceutical giant, announced on Monday its intention to pursue regulatory approval for its Lyme disease vaccine candidate, VLA1557, a decision that comes despite the shot technically failing…
